Pharmacokinetics and biodistribution of genetically engineered antibodies

Current Opinion in Biotechnology

Volumn 13, Issue 6, 2002, Pages 603-608

  Batra, Surinder K ^a   Jain, Maneesh ^a   Wittel, Uwe A ^a   Chauhan, Subhash C ^a   Colcher, David ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DNA ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; ANTIBODY; IMMUNOGLOBULIN FRAGMENT;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CELL MEDIATED CYTOTOXICITY; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE ACTIVITY; HALF LIFE TIME; HYBRIDOMA; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SCINTIGRAPHY; TISSUE DISTRIBUTION; TUMOR; ANIMAL; BIOSYNTHESIS; GENETICS; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MOLECULAR CLONING; MOUSE; NEOPLASM; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CLONING, MOLECULAR; HUMANS; IMMUNOGLOBULIN FRAGMENTS; METABOLIC CLEARANCE RATE; MICE; NEOPLASMS; PROTEIN ENGINEERING; TISSUE DISTRIBUTION;

EID: 0036898144     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(02)00352-X     Document Type: Review

References (36)

1. Colcher D., Goel A., Pavlinkova G., Beresford G., Booth B., Batra S.K. Effects of genetic engineering on the pharmacokinetics of antibodies. Q J Nucl Med. 43:1999;132-139.
2. Huston J.S., George A.J. Engineered antibodies take center stage. Hum Antibodies. 10:2001;127-142. The review reports the highlights of the 11th Annual International Conference on Antibody Engineering (3-6 December 2000).
3. Hudson P.J. Recombinant antibodies: a novel approach to cancer diagnosis and therapy. Expert Opin Investig Drugs. 9:2000;1231-1242. Genetically engineered antibodies now comprise over 30% of biopharmaceuticals in various clinical trials. This review focuses on the latest developments in the design, production and clinical use of recombinant antibodies for cancer diagnosis and therapy.
4. Colcher D., Pavlinkova G., Beresford G., Booth B.J., Choudhury A., Batra S.K. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med. 42:1998;225-241.
5. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 94:2002;1593-1611.
6. Herbst R.S., Kim E.S., Harari P.M. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther. 1:2001;719-732.
7. Kashmiri S.V., Shu L., Padlan E.A., Milenic D.E., Schlom J., Hand P.H. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma. 14:1995;461-473.
8. Santos A.D., Kashmiri S.V., Hand P.H., Schlom J., Padlan E.A. Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. Clin Cancer Res. 5:1999;3118s-3123s.
9. Kashmiri S.V., Iwahashi M., Tamura M., Padlan E.A., Milenic D.E., Schlom J. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Crit Rev Oncol Hematol. 38:2001;3-16. This review describes the development and characterization of the least immunogenic variants of a humanized antibody using specificity-determining residues (SDRs) that should be sufficient to retain its antigen-binding properties.
10. Ober R.J., Radu C.G., Ghetie V., Ward E.S. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 13:2001;1551-1559. The Fc receptor, FcRn, regulates the serum half-lives of IgG. This interesting study provides a molecular explanation for the enigmatic observation that mouse IgG behaves anomalously in humans.
11. Ghetie V., Ward E.S. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today. 18:1997;592-598.
12. Leung S.O., Qu Z., Hansen H.J., Shih L.B., Wang J., Losman M.J., Goldenberg D.M., Sharkey R.M. The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments. Clin Cancer Res. 5:1999;3106s-3117s.
13. Mueller B.M., Reisfeld R.A., Gillies S.D. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA. 87:1990;5702-5705.
14. Slavin-Chiorini D.C., Kashmiri S.V., Lee H.S., Milenic D.E., Poole D.J., Bernon E., Schlom J., Hand P.H. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm. 12:1997;305-316.
15. Hornick J.L., Sharifi J., Khawli L.A., Hu P., Bai W.G., Alauddin M.M., Mizokami M.M., Epstein A.L. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. J Nucl Med. 41:2000;355-362.
16. Hu S., Shively L.F., Raubitschek A.F., Sherman M.F., Williams L.F., Wong J.Y., Shively J.E., Wu A.M. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:1996;3055-3061.
17. Yazaki P.J., Wu A.M., Tsai S.W., Williams L.E., Ikler D.N., Wong J.Y., Shively J.E., Raubitschek A.A. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem. 12:2001;220-228.
18. Colcher D., Pavlinkova G., Beresford G., Booth B.J., Batra S.K. Single-chain antibodies in pancreatic cancer. Ann NY Acad Sci. 880:1999;263-280.
19. Pavlinkova G., Beresford G.W., Booth B.J., Batra S.K., Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of mAb CC49 in colon carcinoma xenografts. J Nucl Med. 40:1999;1536-1546.
20. Pavlinkova G., Colcher D., Booth B.J., Goel A., Batra S.K. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct. Cancer Immunol Immunother. 49:2000;267-275.
21. Pavlinkova G., Colcher D., Booth B.J., Goel A., Wittel U.A., Batra S.K. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs. Int J Cancer. 94:2001;717-726.
22. Kuan C.T., Wikstrand C.J., Archer G., Beers R., Pastan I., Zalutsky M.R., Bigner D.D. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer. 88:2000;962-969.
23. Fujimori K., Covell D.G., Fletcher J.E., Weinstein J.N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med. 31:1990;1191-1198.
24. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., Marks J.D., Weiner L.M. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61:2001;4750-4755. The results presented here indicate that exceedingly high-affinity scFvs display impaired tumor penetration properties that may decrease the efficacy of scFv-targeted therapies. These considerations may not be as important when unconjugated antibodies are used to perturb cellular signaling or to promote antibody-dependent cellular cytotoxicity.
25. Onda M., Nagata S., Tsutsumi Y., Vincent J.J., Wang Q., Kreitman R.J., Lee B., Pastan I. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res. 61:2001;5070-5077. This paper describes that changing many basic residues to neutral or acidic residues in the framework regions can lower the pI of the Fv. This may be a general approach to diminish the nonspecific toxicity of recombinant immunotoxins and other Fv fusion proteins without losing antitumor activity.
26. Pavlinkova G., Beresford G., Booth B.J., Batra S.K., Colcher D. Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. Nucl Med Biol. 26:1999;27-34.
27. Kim I.S., Yoo T.M., Kobayashi H., Kim M.K., Le N., Wang Q.C., Pastan I., Carrasquillo J.A., Paik C.H. Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc. Bioconjug Chem. 10:1999;447-453.
28. Willuda J., Kubetzko S., Waibel R., Schubiger P.A., Zangemeister-Wittke U., Pluckthun A. Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem. 276:2001;14385-14392.
29. Schultz J., Lin Y., Sanderson J., Zuo Y., Stone D., Mallett R., Wilbert S., Axworthy D. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 60:2000;6663-6669.
30. Hudson P.J., Kortt A.A. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods. 231:1999;177-189.
31. Goel A., Beresford G.W., Colcher D., Pavlinkova G., Booth B.J., Baranowska-Kortylewicz J., Batra S.K. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. J Biochem (Tokyo). 127:2000;829-836.
32. Goel A., Colcher D., Baranowska-Kortylewicz J., Augustine S., Booth B.J., Pavlinkova G., Batra S.K. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 60:2000;6964-6971.
33. 131I-labeled multivalent CC49 single-chain Fvs. Clin Cancer Res. 7:2001;175-184.
34. Goel A., Baranowska-Kortylewicz J., Hinrichs S.H., Wisecarver J., Pavlinkova G., Augustine S., Colcher D., Booth B.J., Batra S.K. 99mTc-labeled divalent and tetravalent CC49 single-chain Fvs: novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med. 42:2001;1519-1527. Radioimmunopharmaceutical agents are providing rapid high-resolution imaging, high tumor-to-background ratios, and minimal immunogenicity for cancer diagnosis and imaging. This paper demonstrates that 99mTc-labeled multivalent scFvs show good tumor-targeting characteristics and high radiolocalization indices (tumor-to-background ratio). These reagents, therefore, have the potential for use in clinical imaging studies of cancer in the field of nuclear medicine.
35. Xu X., Clarke P., Szalai G., Shively J.E., Williams L.E., Shyr Y., Shi E., Primus F.J. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res. 60:2000;4475-4484.
36. Cooke S.P., Boxer G.M., Lawrence L., Pedley R.B., Spencer D.I., Begent R.H., Chester K.A. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res. 61:2001;3653-3659.